Johnson & Johnson leads $100 million bet on Delix's non-hallucinogenic psychedelics

The deal and who backed it

Johnson & Johnson is putting fresh capital behind Delix via its venture arm, fronting a $100 million round that Delix said drew more demand than it could fill. The Dementia Discovery Fund, managed by SV Health Investors, co-led the financing. A spokesperson for J&J's venture arm would not comment on the Delix deal. Trade outlet Psychedelic Alpha previously reported that J&J had a term sheet in place to head the round.

Delix is privately held, has raised $115 million before this round, and did not share a valuation. The company said the new cash will push its top depression program into mid-stage trials next year.

What Delix is building

Delix's lead candidate, zalsupindole, is designed to spark neuroplasticity, the brain's wiring-and-rewiring process. The pitch is simple for patients and payers: keep the therapeutic upside associated with psychedelics while stripping out hallucinations and the clinic time that goes with them. In contrast, Johnson & Johnson's Spravato is a ketamine-based nasal spray for depression; it has become a multibillion-dollar franchise yet can only be given with clinician oversight. Delix is developing an oral pill meant for use at home.

In an initial study with 18 patients, those who received zalsupindole saw depression scores drop by roughly half, and the benefit persisted four weeks after the last dose. Even so, the findings require validation in a larger trial that includes a placebo arm, and the company is in the process of preparing the data for submission to a journal.

Smart investors look for new tools that can give a thoughtful edge. We're hosting our first ever investor livestream on 11/17 to show you how to use ChatGPT and Claude to invest like a pro, hosted by Briefs Finance CEO Jaspreet Singh. Save your seat.

Timelines, competition and market

Delix is eyeing an IPO as soon as next year, depending on markets and clinical progress.

Chief Executive Officer Mark Rus said, "I think interest in the space has never been higher." He helped launch ADHD therapy Vyvanse at Shire Plc before that company was acquired by Takeda Pharmaceutical. He also expects a few large drugmakers to build real businesses here in the 2030s.

Big pharma attention is rising, with AbbVie and Eli Lilly among the names exploring the area, and even the Trump administration showing interest. Research firm Grand View Research projects psychedelic medicines could total $11.7 billion by 2033. Delix is also advancing other psychedelic-inspired compounds for substance use conditions, schizophrenia, and neurodegenerative disorders including Alzheimer's and Parkinson's.

Why it matters for your portfolio

This is a bet on a cleaner delivery model rather than on clinic-heavy psychedelics. If Delix can show durable benefit without trips or supervision, the addressable market looks wider and the economics simpler, which helps margins. J&J already owns a depression brand with Spravato, so its check here signals it sees room for an at-home option. The near-term catalysts are clear too: trial start in early 2027 and a data read in early 2028, plus potential IPO optionality if the window opens.

Learning how emerging technology can sharpen your investment decisions pays off. On 11/17, our CEO Jaspreet Singh goes live for our first ever investor livestream on how to use ChatGPT and Claude to invest like a pro. Register to join him.